ImmunoVaccine Technologies, Inc. (IMV Inc.)
8 clinical trials · Sponsor
◉ Watch ImmunoVaccine Technologies, Inc. (IMV Inc.)
| Record | Firm | Date |
|---|---|---|
| Maveropepimut-S (MVP-S) and Low-Dose CPA in Patients With Platinum-Resistant Ovarian Cancer (NCT05243524) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2022-08-05 |
| DPX-Survivac and Pembrolizumab With and Without Intermittent Low-Dose Cyclophosphamide, in Subjects With Relapsed/Refractory Diffuse Large B-Cell Lymphoma (NCT04920617) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2021-06-18 |
| Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors (NCT03836352) | ImmunoVaccine Technologies, Inc. (IMV Inc.) | 2018-12-21 |
Track ImmunoVaccine Technologies, Inc. (IMV Inc.) automatically
Every clearance here is in the API, with alerts when new ones post.